FDA vs. EU MDR
Understanding the Key Regulatory Differences
Navigating global regulatory frameworks is a significant challenge for medical device manufacturers, particularly when aiming to market products in both the United States and the European Union.
The U.S. Food and Drug Administration (FDA) and the European Union Medical Device Regulation (EU MDR) represent two of the most influential and distinctly different regulatory systems in the world.
While both share a common goal of ensuring the safety and effectiveness of medical devices, they differ fundamentally in structure, expectations, and processes.
These differences lead to substantial complications for companies seeking dual-market access, requiring a nuanced understanding of both regimes and often resulting in increased time, cost, and resource burdens.
The following table highlights key areas where these regulatory systems diverge and the practical implications of managing compliance across both jurisdictions.
Aspect
|
US FDA
|
EU MDR
|
Complications
|
| Complications |
Follows a more prescriptive, rule-based system under 21 CFR Part 820. |
Adopts a principle-based, risk-driven approach |
Harder to align documentation and quality strategy across markets |
| Device Classification |
Class I, II, III |
Class I, IIa, IIb, III |
Devices that are low-risk under FDA (Class I) may fall into higher-risk categories under MDR, requiring more scrutiny and Notified Body involvement. |
| Clinical Evidence Expectations |
Allows equivalence for 510(k) with limited data |
Requires robust clinical evaluation even for Class IIa |
MDR restricts equivalence, making it harder to leverage FDA approvals. |
| Post-Market Surveillance (PMS) Complexity |
Event-driven (e.g., MDRs) |
Proactive PMS, trend reporting, PSUR, PMCF required |
Continuous reporting obligations even without adverse events in EU |
| Documentation and Technical File Requirements |
Structured per submission type (510(k), PMA, De Novo) |
Requires a highly structured Technical Documentation file (Annex II and III) and strict adherence to General Safety and Performance Requirements (GSPR). |
Manufacturers must expand/rewrite documentation for MDR, even for the same product, increasing workload |
| Notified Bodies vs. Direct Review |
FDA mostly reviews directly or via accredited third-party reviewers |
Reviewed by Notified Bodies (NBs) designated by EU |
NB scarcity causes long delays (12–24 months) vs. faster FDA timelines. |
| Software as a Medical Device (SaMD) Complications |
Follows IMDRF guidance; more flexible and lower-risk entries. |
Often classified as Class IIa or higher; strict cybersecurity and validation required |
Same software can face stricter MDR requirements incl. cybersecurity and clinical validation. |
| UDI & Device Databases |
Fully implemented UDI system linked to GUDID |
EUDAMED UDI is still in phased rollout |
Requires separate UDI formats and system integration; adds cost and complexity |
| Cost & Timelines |
Fixed and predictable submission fees; relatively faster timelines |
Higher indirect costs due to NB fees, document expansion, and longer review times |
Leads to strategic withdrawals or delays by small firms from the EU market. |
| Dual Compliance Burden |
U.S.-specific QMS and labeling |
EU-specific systems and PMS requirements |
Maintaining two distinct regulatory frameworks adds operational complexity and delays |